

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 5 : C12N 15/87, 15/00, A01K 67/027 C12N 5/10</p>		A1	<p>(11) International Publication Number: WO 93/05165 (43) International Publication Date: 18 March 1993 (18.03.93)</p>
<p>(21) International Application Number: PCT/GB92/01651 (22) International Filing Date: 10 September 1992 (10.09.92)</p>		<p>(74) Agent: GILL JENNINGS & EVERY; 53-64 Chancery Lane, London WC2A 1HN (GB).</p>	
<p>(30) Priority data: 9119338.3 10 September 1991 (10.09.91) GB</p>		<p>(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).</p>	
<p>(71) Applicant (<i>for all designated States except US</i>): AGRICULTURE AND FOOD RESEARCH COUNCIL [GB/GB]; INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS RESEARCH, Babraham Hall, Cambridge CB2 4AT (GB).</p> <p>(72) Inventor; and (73) Inventor/Applicant (<i>for US only</i>): BRUGGEMANN, Marianne [GB/GB]; 2 Station Road, Foxton, Cambridge CB2 6SA (GB).</p>		<p>Published <i>With international search report.</i></p>	
<p>(54) Title: YEAST ARTIFICIAL CHROMOSOMES AND THEIR USE IN THE CONTROL OF GENE EXPRESSION</p>			
<p>(57) Abstract</p> <p>Embryonic stem cells or other cells (not prokaryotic or yeast) that are essentially free of yeast DNA are prepared from suitably marked yeast artificial chromosomes and used to transfer DNA segments of considerable size into organisms.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinea	NO	Norway
BG	Bulgaria	GR	Greece	NZ	New Zealand
BJ	Benin	HU	Hungary	PL	Poland
BR	Brasil	IE	Ireland	PT	Portugal
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CC	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovak Republic
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CS	Czechoslovakia	LU	Luxembourg	SU	Soviet Union
CZ	Czech Republic	MC	Monaco	TD	Chad
DE	Germany	MG	Madagascar	TG	Togo
DK	Denmark	MI	Mali	UA	Ukraine
ES	Spain			US	United States of America

YEAST ARTIFICIAL CHROMOSOMES AND THEIR USE IN THE
CONTROL OF GENE EXPRESSION

Field of the Invention

5 This invention relates to yeast artificial chromosomes and their manipulation and transfer into cells and animals, to exploit the control of gene expression, and also to the resulting cells and animals.

Background of the Invention

10 The ability to transform suitable hosts with foreign DNA, and thus to express gene products not normally produced by the host, is an important goal of biotechnological research. Microorganisms can be used to produce desired proteins, while higher animals having desirable characteristics have also been produced. For 15 example, EP-A-0264166, WO-A-8800239, WO-A-8801648, WO-A-9005188 and WO-A-9211358 describe the use of lactating animals to express foreign proteins which are produced in the milk and can be isolated therefrom; this provides a very satisfactory, controlled source of pure protein.

20 Techniques to transfer cloned DNA into mammalian cells and transgenic animals have greatly facilitated the study of gene regulation and expression. Gene transfection experiments have also highlighted the fact that the limited size of many cloned DNA molecules prevents the efficient 25 use of the numerous distant regulatory sequences believed to control expression.

More particularly, in order to investigate regulation of complex loci and chromosomal domains harbouring clusters of genes, it is essential to introduce very large pieces of 30 DNA into cells and animals. The conventional approaches used in transgenic animal technology have limitations, making it difficult to introduce DNA fragments which are greater than 100 kb; see Brüggemann *et al.*, Eur. J. Immunol. 21:1323-1326 (1991). For example, while germ line-dependent genomic imprinting may affect large areas in 35 which a number of genes may be similarly regulated, there is no efficient method to study such "imprinted" domains.

A satisfactory technique for introducing large DNA fragments would allow progress, and also facilitate the analysis of other complex loci such as the T-complex (harbouring specific deletions) for which a number of genes have been mapped which are crucial for mammalian development. In order to obtain a better understanding of the regulation of eukaryotic genes, it would be desirable to express these genes in their authentic genomic context after cloning and re-introduction into cells.

The expression of mammalian genes is controlled at various levels: the genomic context (influence of neighbouring genes), regulatory elements proximal to the exons (e.g. promoters), regulatory sequences downstream of the termination codon (polyadenylation site) and regulatory motifs further away from coding sequences (e.g. enhancers). For immunoglobulin genes, it has been shown that expression of transgenes is poor when enhancer motifs are missing, and that these can be several thousand base-pairs away (25 kb for the heavy chain 3'-enhancer) from the nearest exon.

Mouse models have been established to address the question of the immunogenicity of chimaeric, foreign and authentic antibodies used for therapeutic purposes; see Brüggemann *et al.*, J. Exp. Med. 170:2153 (1989). It became clear that only authentic proteins escape the surveillance of the immune system.

The techniques currently used for making human antibodies involve either *in vitro* immunisation and immortalisation of human lymphocytes or genetic engineering. The selection of rare specific antibody-producing human lymphocytes outside the body is difficult and, once the lines are obtained, their yield and stability are poor; see Borrebaeck, Immunol. Today 9:355 (1988). Genetic engineering (also termed "humanisation" of rodent antibodies) firstly has to be done for each individual mouse or rat antibody of therapeutic use and secondly does not yield completely human antibodies; see Riechmann *et al.*, Nature 332:323 (1988). "Humanising" existing rodent

antibodies already approved for therapy is currently the most successful way to obtain less immunogenic reagents. However, it would be a considerable improvement to have a mouse strain available which makes authentic human antibodies after immunisation with human materials.

5 A repertoire of immunoglobulins has been obtained from transgenic mice carrying inserted human antibody gene segments in germ line configuration; see WO-A-9004036 and Brüggemann *et al*, PNAS 86:6709 (1989). A human mini IgH 10 locus has been constructed with variable region genes (Vs), diversity segments (Ds), joining segments (Js) and the μ constant region gene (C μ). The human gene segments rearrange in the lymphoid tissue of these mice (VDJ-C μ) and 15 antibodies with human μ heavy chains can be obtained after immunisation. However, the level of human IgM as opposed to mouse IgM is low, and specific hybridomas with human μ chains are rare after immunisation. A further complication is that most of those cells that produce human heavy chain 20 also secrete endogenous mouse Ig. This means that rearrangement of human μ does not stop endogenous rearrangement; in other words, allelic exclusion is not achieved. Furthermore, the actual repertoire size of the 25 produced human antibodies is unknown but might be small as the IgH construct contains only a limited number of V and D segments.

Srivastava *et al*, Gene 103:53-59 (1991), describe plasmids which permit the insertion of neomycin-resistance gene into the human DNA insert or the vector arm of a YAC. In the latter case, the plasmid also contains a LYS2 gene 30 for selection in a yeast host. The URA3 gene is then replaced by a new insert, thus inactivating URA.

Bothstein *et al*, Science 240:1439-1443 (1988), describe the practical advantages of the yeast organism for cloning and manipulating large DNA molecules. Green *et al*, 35 Science 250:94-98 (1990), report the cloning of segments of up to one million base-pairs in yeast cells in artificial chromosomes (YACs), allowing the long-range mapping and

analysis of complex genomes. Yeast vectors for cloning of large DNA molecules combine two features; plasmid sequences for their propagation in *E. coli* and yeast specific sequences to ensure the replication and maintenance of a linear molecule when grown in yeast.

Nevertheless, the problem of producing large molecules (of which specific examples are immunoglobulins, Factor VIII and Factor IX) on a commercial scale, remains. At the molecular level, it would be desirable to introduce large DNA molecules containing single genes of considerable size, in order to facilitate correct expression. For example, the human Ig heavy chain locus accommodating all Vs, Ds, Js and C regions is estimated to spread over 3000 kb of DNA; the Factor VIII gene is almost 200 kb in size with 23 exons. At present, high level of expression is rarely achieved by the introduction of cDNAs and engineers genomic "minigenes" into transgenic animals.

Summary of the Invention

Surprisingly, it has now been found that specific DNA of considerable length can be introduced into ES cells via a YAC, without introducing DNA from the yeast. The need to purify the YAC out of yeast is thus avoided, and transformation is essentially foolproof. This discovery is applicable to the introduction of such DNA into other cells also.

The appropriate YAC, for use in the present invention, includes a foreign gene or gene locus (i.e. including one or more genes or gene segments) of at least 100 kb and also a marker gene which allows selection in cells that are not prokaryotic or yeast cells. This construct can be obtained by integration of the marker gene, e.g. Neo', into a YAC including the foreign gene.

In a further aspect of the invention, ES cells or other cells are transformed by the marked YAC, and thus can be selected and inserted into, say, animals which consequently express human immunoglobulin or other genes. In particular, a transgenic lactating, ovine or bovine

animal, mouse or other rodent, or any non-human animal, may contain a foreign gene or gene locus of considerable length, e.g. at least 100 kb, often at least 300 kb, but also 1 Mb or more, if required. The animal may express the 5 product of another animal, e.g. a human product, but not its own corresponding product.

Description of the Invention

The available YACs contain a marker gene that allows for selection in prokaryotic cells, e.g. for ampicillin-10 resistance, but do not contain a marker gene that would allow for selection for integration in eukaryotic, ES, somatic or mammalian cells. This invention utilises the recombination proficiency of yeast to introduce an antibiotic resistance into the YAC by recombination. For 15 example, neomycin-resistance gene controlled by the thymidine kinase promoter (^{tk}neo) will allow selection in mammalian cells. Other suitable markers are hygromycin and HPRT-resistance. Depending on the circumstances, it may be desirable to prepare YACs with different markers, for 20 integration.

The present invention is based in part on the realisation that yeast vectors with dominant selectable marker genes allow targeted integration into left (centromeric) and right (non-centromeric) YAC arms as well 25 as alterations to human-derived insert DNA. In transformation experiments, integration proceeds exclusively by homologous recombination, although yeast prefers linear ends of homology for predefined insertions. Targeted regions can be rescued which expedite the cloning 30 of internal human sequences and the identification of 5' and 3' YAC/insert borders. Integration of, say, the neomycin-resistance gene into various parts of the YAC allows the transfer and stable integration, and also 35 rescue, of large DNA molecules into a variety of mammalian cells including embryonic stem cells.

The present invention utilises YACs as cloning vehicles for the complete integration of DNA of a length

that has previously been difficult to transfer. The invention also allows specific modification of the DNA.

It may be necessary to enlarge an existing YAC containing heavy and light chain genes. A variety of human

5 heavy and light chain-containing cosmids is available; they may be added on to the YAC by homologous, site-specific or other integration. Further, YACs containing different or overlapping parts of defined loci may be crossed, in order to obtain a contiguous DNA molecule in one YAC. This 10 allows a large part of the human heavy and light chain gene clusters to be reconstituted, and to obtain transgenic animals which make authentic human antibodies.

Similarly, a Factor IX-containing YAC may be modified in order to direct expression, for example, in milk. This 15 may involve exchanging the Factor IX promoter for a milk gene promoter, e.g. the murine whey acidic protein gene promoter, by homologous recombination in yeast. Factor VIII is another product that can be produced in the same way.

20 It is an important feature of the invention that the marker gene is incorporated into YAC in an active form, in order to allow selection. For this purpose, the YAC without that marker is subjected to integration with a plasmid containing the marker gene and a sequence outside 25 the foreign gene, e.g. the ampicillin-resistance gene. This may lead to a YAC containing multiple copies of both markers, and duplication at least is preferred, but the important point is that, say, neomycin-resistance can be observed.

30 The starting materials and techniques for use in the invention are generally known, or the materials can be prepared by known techniques. For example, several separately-derived embryonic stem (ES) cell lines are available: see Mansour *et al*, *Nature* 336:348 (1988); 35 Schwartzberg *et al*, *Science* 246:799 (1989); Johnson *et al*, *Science* 245:1234 (1989); and Zijlstra *et al*, *Nature* 342:435 (1989). Transformation and selection procedures have

already been established. Immunoglobulin genes on YACs are available, as is a YAC containing the Factor IX gene; these clones have been obtained independently by screening various YAC libraries; see Little *et al*, PNAS USA 86:1598 (1989). The sizes for the YACs vary and are between 200 and 600 kb. Cosmids may increase size to, say, 1.8 Mb.

The methods concerned with the introduction of large DNA molecules into cells are microinjection and co-precipitation with calcium phosphate (using any naked DNA such as YACs, genomic DNA or dissected chromosomes) or protoplast fusion, using yeast protoplasts: see Oi *et al*, PNAS USA 80:825-829 (1983); Graham and van der Eb, Virol. 52:456-658 (1973); and Richa and Lo, Science 245:175-177 (1989). The approach of directly injecting large DNA molecules into fertilised eggs or ES cells was difficult because of the nature of DNA (large molecules are sticky). It is preferred to introduce the various YACs by protoplast fusion; this, however, needs the introduction of a selective marker gene into the YAC (see below). Another approach is the transfection of high molecular weight DNA or chromosomal DNA, mixed with selective marker DNA, into ES cells by calcium phosphate co-precipitation. Identification of integrated genes of interest could then be done by probing with human Alu repeat sequences, confirming integration and size, as well as with specific probes. This random approach is similar to a library screening and depends on the transfection frequencies. Multiple copies of selective marker genes may thus be produced.

It is a primary object of the invention to introduce large DNA molecules into the germ line of mice or other non-human animals, e.g. via ES cells. For the purposes of this invention, such large molecules should be introduced in germ line configuration. By introducing them into ES cells, the germ line locus, e.g. for antibodies or immunoglobulins, rearranges in the lymphoid tissue of the animal, and thus antibody production takes place.

Techniques outlined above make use of YACs that contain, for example, well-characterised parts of the human immunoglobulin light and heavy chain loci or the Factor IX gene. In addition, high molecular weight DNA carrying any (large) genes of interest may be transferred into a variety of cells, including ES cells which can and have been used to obtain transgenic mice.

The purpose of introducing coding sequences and flanking regions on large DNA molecules is to preserve the original genomic context which facilitates the correct expression. These techniques also allow the introduction and study of large gene families. In combination with gene targeting, authentic foreign proteins can be obtained in large yield without interference of the homologous endogenous gene products. In that way, an animal may be obtained with an immune system (in respect of antibody production) indistinguishable from that of man.

The endogenous mouse antibodies may interfere with the transgenic human immunoglobulins. It may therefore be necessary to silence the mouse immunoglobulin heavy and light chain loci by gene targeting in ES cells. A mouse strain can then be obtained with a transgenic human immunoglobulin heavy and light chain gene cluster, that makes no antibodies of its own.

In a particular example of the invention, a neomycin resistance cassette was integrated into a large (300 kb) YAC. The YAC contains a well-characterised region of the human immunoglobulin (Ig) kappa (κ) light chain locus. The modified Igκ YAC was transferred into embryonic stem (ES) cell lines by spheroplast fusion. The approach is useful for the transfer and expression of large genes and gene families in their original genomic context into the germline of other species via ES cells.

The κ locus in humans is estimated to spread over 2500 thousand base-pairs of DNA. The genes of the immunoglobulin κ light chain are assembled during B-cell differentiation by somatic recombination: one of the many

V_κ (V=variable) gene segments rearranges with one of the five J_κ (J=joining) segments, and a C_κ (C=constant region) polypeptide is transcribed. In order to investigate the expression of such complex loci, it is essential to 5 introduce very large fragments, containing many gene segments as well as necessary regulatory sequences, into cells and animals.

ES cells are suitable for gene manipulation experiments such as the introduction of large DNA molecules 10 on YACs. Furthermore, ES cells can be reintroduced into blastocysts, and chimaeric and germline mice which carry the introduced loci can be derived from them.

The invention is further illustrated by the specific description that follows, and also by the Materials and 15 Methods section of Davies *et al*, Nucleic Acids Research 20(11):2693-2698 (1992). The contents of that article are incorporated herein by reference.

The YAC containing the human κ locus does not contain a marker gene which allows selection in ES cells. 20 Therefore, in accordance with one embodiment of the invention, the neomycin resistance gene (neo) was integrated into the YAC. The neo gene permits selection of stable clones when transferred into mammalian cells. An example of the yeast-selectable marker gene that is also 25 usually used is LYS2 which allows growth in lysine-deficient yeast media. Integration of exogenous DNA in yeast proceeds in an homologous fashion, and introducing new sequences into YACs, termed "retrofitting" by Eliceiri *et al*, PNAS USA 88:2179-2183 (1991) is facilitated because 30 of the plasmid homology region of the YAC arms.

Targeted integration in yeast is either performed using replacement constructs or integration vectors; see Scherer *et al*, PNAS USA 76:4951-4955 (1979); Pavan *et al*, Mol. Cell. Biol. 10:4163-4169 (1990), and PNAS USA 88:7788-35 7791 (1991); and Srivastava *et al*, supra. Replacement vectors are designed to disrupt a region of homology by the insertion of exogenous DNA. In the particular example,

homologous integration into YACs was studied using integration vectors which recombine as a whole and duplicate a given target sequence without impairing its function. Integration vectors can be rescued from YACs and 5 also from transfected cells, as the bacterial sequences allow subcloning in bacteria, for example, and this permits the isolation of flanking insert DNA. The universal principle of integration using a set of vectors, several targeting sites and different YACs is shown. The modified 10 YACs have been stably introduced into embryonic stem cells: thus, the experiments show the feasibility of transferring complex gene loci from one species to another.

An important aspect of the evidence is that YACs can be used to transfer such loci into other cells, without 15 transferring potentially-undesirable yeast DNA, while retaining the locus in its essential configuration and size.

CLAIMS

1. A cell that is not prokaryotic or a yeast cell, transformed with a foreign gene or gene locus of at least 100 kb and also a marker gene which allows selection in the 5 or another such cell.
2. A cell according to claim 1, which is an embryonic stem cell.
3. A cell according to claim 1 or claim 2, wherein the 10 marker gene is in addition to an ampicillin-resistance or other prokaryotic selective marker gene and/or uracil-resistance or other yeast-selective marker gene.
4. A cell according to any preceding claim, comprising at least two copies of the or each marker gene.
5. A cell according to any preceding claim, wherein the 15 foreign gene or gene locus is in germ line configuration.
6. A cell according to any preceding claim, essentially free of yeast DNA.
7. A yeast artificial chromosome (YAC) including a 20 foreign gene or gene locus of at least 100 kb and also a marker gene which allows selection in cells that are not prokaryotic or yeast cells.
8. A YAC according to claim 7, wherein the marker is for resistance to neomycin, hygromycin or HPRT.
9. A YAC according to claim 7 or claim 8, wherein the 25 foreign gene or gene locus and/or the marker gene are as defined in any of claims 3 to 5.
10. A transgenic non-human animal including a foreign gene or gene locus of at least 100 kb.
11. A transgenic non-human animal capable of expressing a 30 the product of another animal but not its own corresponding product.
12. An animal according to claim 11, wherein said another animal is human.
13. An animal according to claim 10 and also claim 11 or 35 claim 12.
14. An animal according to any of claims 10 to 13, which is a lactating animal and the gene product is isolatable from its milk.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 92/01651

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶			
According to International Patent Classification (IPC) or to both National Classification and IPC			
Int.Cl. 5 C12N15/87; C12N15/00; A01K67/027;		C12N5/10	
II. FIELDS SEARCHED			
Minimum Documentation Searched ⁷			
Classification System		Classification Symbols	
Int.Cl. 5		C12N	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸			
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹			
Category ¹⁰	Citation of Document ¹¹ with indication, where appropriate, of the relevant passages ¹²		Relevant to Claim No. ¹³
P, X	<p>NUCLEIC ACIDS RESEARCH. vol. 20, no. 11, 11 June 1992, ARLINGTON, VIRGINIA US pages 2693 - 2698 DAVIES, N. P. ET AL. 'Targeted alterations in yeast artificial chromosomes for inter-species gene transfer' cited in the application see the whole document</p> <p>---</p>		1-11
P, X	<p>NUCLEIC ACIDS RESEARCH. vol. 20, no. 12, 13 July 1992, ARLINGTON, VIRGINIA US pages 3073 - 3077 SCHEDL, A. ET AL. 'Transgenic mice generated by pronuclear injection of a yeast artificial chromosome' see the whole document</p> <p>---</p>		1-11
			-/-
<p>¹⁰ Special categories of cited documents: ¹¹ A document defining the general state of the art which is not considered to be of particular relevance ¹² earlier document but published on or after the international filing date ¹³ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) ¹⁴ document referring to an oral disclosure, use, exhibition or other means ¹⁵ document published prior to the international filing date but later than the priority date claimed</p> <p>¹⁶ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention ¹⁷ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step ¹⁸ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art ¹⁹ document member of the same patent family</p>			
IV. CERTIFICATION			
Date of the Actual Completion of the International Search 10 DECEMBER 1992		Date of Mailing of this International Search Report 21.12.92	
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer CHAMBONNET F.J.	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	EP, A, 0 375 406 (THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA) 27 June 1990 see the whole document ---	1, 2, 5, 6, 10-13
A	NATURWISSENSCHAFTEN. vol. 74, no. 2, February 1987, BERLIN DE pages 78 - 85 ROTH, G.E. "Artifizielle" chromosomen' see page 82, column 2, line 27 - page 85, line 4 ---	1-9
P, X	EMBO JOURNAL. vol. 11, no. 2, February 1992, EYNSHAM, OXFORD GB pages 417 - 422 STRAUSS, W.M. & JAENISCH, R. 'Molecular complementation of collagen mutation in mammalian cells using yeast artificial chromosomes' see the whole document ---	1, 3, 7-9
X	EMBO JOURNAL. vol. 10, no. 7, July 1991, EYNSHAM, OXFORD GB pages 1629 - 1634 GNIRKE, A. ET AL. 'Cloning and the in vivo expression of the human GART gene using yeast artificial chromosomes' see the whole document ---	1, 7
X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 88, March 1991, WASHINGTON US pages 2179 - 2183 ELICEIRI, B. ET AL. 'Stable integration and mouse expression in mouse cells of yeast artificial chromosomes harboring human genes' cited in the application see the whole document ---	1, 7
X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 87, July 1990, WASHINGTON US pages 5109 - 5113 PACHNIS, V. ET AL. 'Transfer of a yeast artificial chromosome carrying human DNA from <i>Saccharomyces cerevisiae</i> into mammalian cells' see the whole document ---	1, 7
		-/-

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
P,X	WO,A,9 203 918 (GENPHARM INTERNATIONAL) 19 March 1992 see claims 92-101 -----	1,7

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. GB 9201651
SA 64230

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 10/12/92

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0375406	27-06-90	AU-B-	627256	20-08-92
		AU-A-	4701589	28-06-90
		CA-A-	2006011	21-06-90
		CN-A-	1046936	14-11-90
		JP-A-	3094626	19-04-91
		WO-A-	9006992	28-06-90
WO-A-9203918	19-03-92	AU-A-	8507191	30-03-92